ChinaDrugStatus
National Reimbursement Drug List (Basic Medical Insurance)

2026 China NRDL Changes

Verified comparison of the 2026 NRDL against the 2025 baseline edition (医保发〔2025〕33号). Launch sample includes 15 manually audited changes across additions, all 4 non-renewed transition removals, and major payment scope expansions.

2026 catalogs published Nov 14, 2026·Effective Jan 1, 2027

DrugChange Type & SummaryStatusEffective / TransitionSource
Mazdutide
玛仕度肽
Not in 2025 → 2026 #30
Added

Newly added to 2026 NRDL Negotiated List (#30, Class B, price redacted *); restricted to adults with Type 2 Diabetes mellitus (weight management indication not reimbursed).

新增纳入2026版谈判药品第30项(乙类,支付标准*),限成人2型糖尿病患者;协议期2027-01-01至2028-12-31。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
NHSA · PDF p.119
Verified 2026-11-20
Relmacabtagene autoleucel
瑞基奥仑赛
Not in 2025 → 2026 #297
Added

Newly added to 2026 NRDL Negotiated List (#297, Class B, *) across 3 lymphoma indications (r/r LBCL, r/r FL, r/r MCL); transitioned out of the 2025 Commercial List (#12).

由2025版商保创新药目录(第12项)转入2026版基本医保谈判药品第297项(乙类,支付标准*),覆盖LBCL、FL及MCL三项适应症。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
NHSA · PDF p.149
Verified 2026-11-20
Insulin icodec / Semaglutide
依柯胰岛素司美格鲁肽
Not in 2025 → 2026 #18
Added

Newly added to 2026 NRDL Negotiated List (#18, Class B, *) for adult T2D inadequately controlled on basal insulin or GLP-1 receptor agonist.

新增纳入2026版谈判药品第18项(乙类,支付标准*),限基础胰岛素或GLP-1受体激动剂控制不佳的成人2型糖尿病患者。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
NHSA · PDF p.118
Verified 2026-11-20
Zolbetuximab
佐妥昔单抗
Not in 2025 → 2026 #287
Added

Newly added to 2026 NRDL Negotiated List (#287, Class B, *) for first-line CLDN18.2+ HER2- locally advanced/metastatic gastric or GEJ adenocarcinoma with chemo.

新增纳入2026版谈判药品第287项(乙类,支付标准*),限一线治疗CLDN18.2阳性、HER2阴性局部晚期或转移性胃/GEJ腺癌。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
NHSA · PDF p.148
Verified 2026-11-20
Datopotamab deruxtecan
德达博妥单抗
Not in 2025 → 2026 #288
Added

Newly added to 2026 NRDL Negotiated List (#288, Class B, *) for adult HR+/HER2- unresectable or metastatic breast cancer after prior ET and ≥1L chemo.

新增纳入2026版谈判药品第288项(乙类,支付标准*),限既往接受过内分泌治疗且晚期经≥1线化疗的HR阳性HER2阴性乳腺癌。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
NHSA · PDF p.148
Verified 2026-11-20
Sapropterin dihydrochloride
盐酸沙丙蝶呤
Not in 2025 → 2026 #42
Added

Newly added to 2026 NRDL Negotiated List (#42, Class B, ¥62.00 per 100mg tablet) for BH4-deficiency HPA; transitioned from the 2025 Commercial List (#2).

由2025版商保创新药目录(第2项)转入2026版基本医保谈判药品第42项(乙类,62.00元/100mg片),限BH4缺乏症所致HPA。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
NHSA · PDF p.120
Verified 2026-11-20
Pamiparib
帕米帕利
2025 #256 → Removed
Removed

Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #256); 6-month transition period under original payment standard runs through Jun 30, 2027.

未成功续约调出2026版目录(原2025版谈判第256项);通知明确给予6个月过渡期,2027年6月30日前可按原支付标准继续支付。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
Transition to Jun 30, 2027
NHSA · Section I(1) Transition Clause
Verified 2026-11-20
Beraprost sodium (sustained-release)
贝前列素钠缓释片
2025 #40 → Removed
Removed

Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #40); 6-month transition period under original payment standard runs through Jun 30, 2027.

未成功续约调出2026版目录(原2025版谈判第40项);通知明确给予6个月过渡期,2027年6月30日前可按原支付标准继续支付。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
Transition to Jun 30, 2027
NHSA · Section I(1) Transition Clause
Verified 2026-11-20
Xiao'er Niuhuang Qingxin San
小儿牛黄清心散
2025 #20 → Removed
Removed

Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated TCM #20); 6-month transition period under original payment standard runs through Jun 30, 2027.

未成功续约调出2026版目录(原2025版谈判中成药第20项);通知明确给予6个月过渡期,2027年6月30日前可按原支付标准继续支付。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
Transition to Jun 30, 2027
NHSA · Section I(1) Transition Clause
Verified 2026-11-20
Shenlong Ningxin Capsules
参龙宁心胶囊
2025 #26 → Removed
Removed

Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated TCM #26); 6-month transition period under original payment standard runs through Jun 30, 2027.

未成功续约调出2026版目录(原2025版谈判中成药第26项);通知明确给予6个月过渡期,2027年6月30日前可按原支付标准继续支付。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
Transition to Jun 30, 2027
NHSA · Section I(1) Transition Clause
Verified 2026-11-20
Dupilumab
度普利尤单抗
2025 #93 → 2026 #104
Payment Scope Changed

Expanded from 1 indication (atopic dermatitis) in 2025 (#93) to 5 indications in 2026 (#104): added prurigo nodularis, asthma (≥6y), eosinophilic COPD, and bullous pemphigoid.

支付范围由2025版单一项(特应性皮炎)扩增至5项,新增结节性痒疹、6岁及以上哮喘、嗜酸性粒细胞升高COPD及大疱性类天疱疮。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
NHSA · PDF p.126
Verified 2026-11-20
Trastuzumab deruxtecan
德曲妥珠单抗
2025 #228 → 2026 #255
Payment Scope Changed

Expanded from 2 breast cancer settings in 2025 (#228) to 7 indications in 2026 (#255), adding HR+ HER2-low/ultralow BC, neoadjuvant HER2+ BC, 2L/3L+ HER2+ gastric/GEJ, and HER2-mutant NSCLC.

支付范围由2025版2项扩增至7项,新增HR+ HER2低/超低表达乳腺癌、HER2+乳腺癌新辅助、HER2+胃/GEJ腺癌(二线及三线以上)及HER2突变NSCLC。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
NHSA · PDF p.142
Verified 2026-11-20
Sacituzumab tirumotecan
芦康沙妥珠单抗
2025 #252 → 2026 #284
Payment Scope Changed

Expanded from 2 indications in 2025 (#252) to 4 indications in 2026 (#284), adding HR+/HER2- breast cancer (post-ET/chemo) and earlier post-EGFR-TKI non-squamous NSCLC.

支付范围由2025版2项扩增至4项,新增HR+/HER2-乳腺癌及经EGFR-TKI治疗进展后的EGFR突变非鳞状NSCLC(无需先经含铂化疗)。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
NHSA · PDF p.147
Verified 2026-11-20
Ivosidenib
艾伏尼布
2025 #258 → 2026 #298
Payment Scope Changed

Expanded beyond r/r IDH1-mutated AML in 2025 (#258) to add first-line newly diagnosed IDH1-mutated AML combined with azacitidine (age ≥75 or intensive-chemo ineligible) in 2026 (#298).

支付范围新增联用阿扎胞苷一线治疗≥75岁或不耐受强诱导化疗的新诊断IDH1突变AML患者(原2025版仅限复发/难治AML)。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
NHSA · PDF p.149
Verified 2026-11-20
Eliglustat tartrate
酒石酸艾格司他
2025 #38 → 2026 #41
Payment Scope Changed

Expanded from adult Gaucher disease type 1 in 2025 (#38, ¥381.00) to add pediatric GD1 patients (age ≥6y, weight ≥15kg, ERT-stable) in 2026 (#41, ¥361.95 per 84mg capsule).

支付范围新增6岁及以上且体重≥15公斤、ERT稳定的Ⅰ型戈谢病儿童患者,支付标准同步由381.00元调整为361.95元(84mg/粒)。

Announced · Effective Jan 1, 2027
Jan 1, 2027
Announced Nov 14, 2026
NHSA · PDF p.119
Verified 2026-11-20